Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Equity Ratio: 2013-2025

Historic Equity Ratio for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to 0.56.

  • Theravance Biopharma's Equity Ratio rose 7.43% to 0.56 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.56, marking a year-over-year increase of 7.43%. This contributed to the annual value of 0.50 for FY2024, which is 11.10% down from last year.
  • As of Q3 2025, Theravance Biopharma's Equity Ratio stood at 0.56, which was up 6.12% from 0.53 recorded in Q2 2025.
  • Theravance Biopharma's 5-year Equity Ratio high stood at 0.73 for Q4 2022, and its period low was -0.99 during Q1 2021.
  • Its 3-year average for Equity Ratio is 0.56, with a median of 0.55 in 2024.
  • Its Equity Ratio has fluctuated over the past 5 years, first plummeted by 281.39% in 2021, then soared by 180.52% in 2022.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Equity Ratio stood at -0.90 in 2021, then spiked by 180.52% to 0.73 in 2022, then decreased by 23.34% to 0.56 in 2023, then dropped by 11.10% to 0.50 in 2024, then rose by 7.43% to 0.56 in 2025.
  • Its Equity Ratio was 0.56 in Q3 2025, compared to 0.53 in Q2 2025 and 0.48 in Q1 2025.